ArticleAntimicrobial agents and chemotherapy2006
Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 148 citations in OpenAlex.
- GNPS Untargeted GC-MS Metabolomic Analysis of Essential Oils From Duguetia lanceolata and Evaluation of Antimicrobial Activity.Chemistry & biodiversity · 2026Article
- Antifungal Susceptibility Data and Epidemiological Distribution ofAntibiotics (Basel, Switzerland) · 2024Article
- Review
- Raman Spectroscopy of OralInternational journal of molecular sciences · 2022Article
- Development of a Multiplex PCR Short Tandem Repeat Typing Scheme for Candida krusei.Journal of clinical microbiology · 2022Article
- Antifungal Susceptibility Testing: A Primer for Clinicians.Open forum infectious diseases · 2021Review
- Review on Current Status of Echinocandins Use.Antibiotics (Basel, Switzerland) · 2020Review
- Genetic Differentiation, Diversity, and Drug Susceptibility ofFrontiers in microbiology · 2018Article
- Antifungal susceptibility testing of Candida species isolated from the immunocompromised patients admitted to ten university hospitals in Iran: comparison of colonizing and infecting isolates.BMC infectious diseases · 2017Article
- Identification of small molecules that disrupt vacuolar function in the pathogen Candida albicans.PloS one · 2017Article
- Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.Antimicrobial agents and chemotherapy · 2015Article
- In vitro antifungal activity of silver nanoparticles against fluconazole-resistant Candida species.World journal of microbiology & biotechnology · 2015Article
- [Strategies for antifungal treatment failure in intensive care units].Der Anaesthesist · 2015Review
- Development of echinocandin resistance in Candida krusei isolates following exposure to micafungin and caspofungin in a BM transplant unit.Bone marrow transplantation · 2015Article
- Potential Use of Phenolic Acids as Anti-Candida Agents: A Review.Frontiers in microbiology · 2015Review
- Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?Intensive care medicine · 2014Review
- In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei.Antimicrobial agents and chemotherapy · 2014Article
- Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.Antimicrobial agents and chemotherapy · 2014Article
- In vitro and in vivo activity of a novel antifungal small molecule against Candida infections.PloS one · 2014Article
- Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents.BioMed research international · 2013Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical failure associated with reduced susceptibility to caspofungin has been described in Candida albicans and C. parapsilosis. We report a case of Candida krusei infection that progressed despite caspofungin therapy. Reduced microbial susceptibility to all three echinocandins (caspofungin, anidulafungin, and micafungin) was noted but was not associated with mutations in FKS1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.